Serelaxin attenuates renal inflammation and fibrosis in a mouse model of dilated cardiomyopathy

Beverly Giam, Po Yin Chu, Sanjaya Kuruppu, A. Ian Smith, Duncan Horlock, Aishwarya Murali, Helen Kiriazis, Xiao-Jun Du, David M. Kaye, Niwanthi W. Rajapakse

Research output: Contribution to journalArticleResearchpeer-review

Abstract

New Findings: What is the central question of this study? The aim was to determine the renoprotective effects of serelaxin in the setting of chronic heart failure. What are the main findings and its importance? Our data indicate that serelaxin can reduce renal fibrosis and inflammation in experimental heart failure. Currently, there are no effective treatments to rescue renal function in heart failure patients, and our data suggest that serelaxin might have the potential to reduce renal fibrosis and inflammation in heart failure. Abstract: Serelaxin has been demonstrated to attenuate renal fibrosis and inflammation in cardiorenal disease. In the present study, we tested the hypothesis that serelaxin can prevent the decline in renal function in dilated cardiomyopathy (DCM) by targeting renal fibrosis and inflammation. Male transgenic mice with DCM (n = 16) and their wild-type littermates (WT; n = 20) were administered either vehicle or serelaxin (500 μg kg−1 day−1; subcutaneous minipumps; 8 weeks). Cardiac function was assessed via echocardiography before and during the eighth week of serelaxin treatment. Renal function and inflammation as well as cardiac and renal fibrosis were assessed at the end of the study. Serelaxin had minimal effect on cardiac function (P ≥ 0.99). Tubulointerstitial and glomerular fibrosis were ∼3-fold greater in vehicle-treated DCM mice compared with vehicle-treated WT mice (P ≤ 0.001). Renal mRNA expression of Tnfα and Il1α were ∼4- and ∼3-fold greater, respectively, in vehicle-treated DCM mice compared with vehicle-treated WT mice (P ≤ 0.05). Tubulointerstitial and glomerular fibrosis were 46 and 45% less, respectively, in serelaxin-treated DCM mice than in vehicle-treated DCM mice (P ≤ 0.01). Renal cortical mRNA expression of Tnfα and Il1α were 56 and 58% less, respectively, in the former group compared with the latter (P ≤ 0.05). The urinary albumin:creatinine ratio was ∼3-fold greater in vehicle-treated DCM mice compared with vehicle-treated WT mice (P = 0.02). The urinary albumin:creatinine ratio was not significantly different between vehicle-treated DCM mice and serelaxin-treated DCM mice (P = 0.38). These data suggest that serelaxin can attenuate renal fibrosis and inflammation and has the potential to exert renoprotective effects in DCM.

Original languageEnglish
Pages (from-to)1593-1602
Number of pages10
JournalExperimental Physiology
Volume103
Issue number12
DOIs
Publication statusPublished - 1 Dec 2018

Keywords

  • cardiorenal syndrome
  • fibrosis
  • inflammation
  • serelaxin

Cite this

Giam, Beverly ; Chu, Po Yin ; Kuruppu, Sanjaya ; Smith, A. Ian ; Horlock, Duncan ; Murali, Aishwarya ; Kiriazis, Helen ; Du, Xiao-Jun ; Kaye, David M. ; Rajapakse, Niwanthi W. / Serelaxin attenuates renal inflammation and fibrosis in a mouse model of dilated cardiomyopathy. In: Experimental Physiology. 2018 ; Vol. 103, No. 12. pp. 1593-1602.
@article{971750aa954844208a9cc247c222f99f,
title = "Serelaxin attenuates renal inflammation and fibrosis in a mouse model of dilated cardiomyopathy",
abstract = "New Findings: What is the central question of this study? The aim was to determine the renoprotective effects of serelaxin in the setting of chronic heart failure. What are the main findings and its importance? Our data indicate that serelaxin can reduce renal fibrosis and inflammation in experimental heart failure. Currently, there are no effective treatments to rescue renal function in heart failure patients, and our data suggest that serelaxin might have the potential to reduce renal fibrosis and inflammation in heart failure. Abstract: Serelaxin has been demonstrated to attenuate renal fibrosis and inflammation in cardiorenal disease. In the present study, we tested the hypothesis that serelaxin can prevent the decline in renal function in dilated cardiomyopathy (DCM) by targeting renal fibrosis and inflammation. Male transgenic mice with DCM (n = 16) and their wild-type littermates (WT; n = 20) were administered either vehicle or serelaxin (500 μg kg−1 day−1; subcutaneous minipumps; 8 weeks). Cardiac function was assessed via echocardiography before and during the eighth week of serelaxin treatment. Renal function and inflammation as well as cardiac and renal fibrosis were assessed at the end of the study. Serelaxin had minimal effect on cardiac function (P ≥ 0.99). Tubulointerstitial and glomerular fibrosis were ∼3-fold greater in vehicle-treated DCM mice compared with vehicle-treated WT mice (P ≤ 0.001). Renal mRNA expression of Tnfα and Il1α were ∼4- and ∼3-fold greater, respectively, in vehicle-treated DCM mice compared with vehicle-treated WT mice (P ≤ 0.05). Tubulointerstitial and glomerular fibrosis were 46 and 45{\%} less, respectively, in serelaxin-treated DCM mice than in vehicle-treated DCM mice (P ≤ 0.01). Renal cortical mRNA expression of Tnfα and Il1α were 56 and 58{\%} less, respectively, in the former group compared with the latter (P ≤ 0.05). The urinary albumin:creatinine ratio was ∼3-fold greater in vehicle-treated DCM mice compared with vehicle-treated WT mice (P = 0.02). The urinary albumin:creatinine ratio was not significantly different between vehicle-treated DCM mice and serelaxin-treated DCM mice (P = 0.38). These data suggest that serelaxin can attenuate renal fibrosis and inflammation and has the potential to exert renoprotective effects in DCM.",
keywords = "cardiorenal syndrome, fibrosis, inflammation, serelaxin",
author = "Beverly Giam and Chu, {Po Yin} and Sanjaya Kuruppu and Smith, {A. Ian} and Duncan Horlock and Aishwarya Murali and Helen Kiriazis and Xiao-Jun Du and Kaye, {David M.} and Rajapakse, {Niwanthi W.}",
year = "2018",
month = "12",
day = "1",
doi = "10.1113/EP087189",
language = "English",
volume = "103",
pages = "1593--1602",
journal = "Experimental Physiology",
issn = "0958-0670",
publisher = "Wiley-Blackwell",
number = "12",

}

Giam, B, Chu, PY, Kuruppu, S, Smith, AI, Horlock, D, Murali, A, Kiriazis, H, Du, X-J, Kaye, DM & Rajapakse, NW 2018, 'Serelaxin attenuates renal inflammation and fibrosis in a mouse model of dilated cardiomyopathy', Experimental Physiology, vol. 103, no. 12, pp. 1593-1602. https://doi.org/10.1113/EP087189

Serelaxin attenuates renal inflammation and fibrosis in a mouse model of dilated cardiomyopathy. / Giam, Beverly; Chu, Po Yin; Kuruppu, Sanjaya; Smith, A. Ian; Horlock, Duncan; Murali, Aishwarya; Kiriazis, Helen; Du, Xiao-Jun; Kaye, David M.; Rajapakse, Niwanthi W.

In: Experimental Physiology, Vol. 103, No. 12, 01.12.2018, p. 1593-1602.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Serelaxin attenuates renal inflammation and fibrosis in a mouse model of dilated cardiomyopathy

AU - Giam, Beverly

AU - Chu, Po Yin

AU - Kuruppu, Sanjaya

AU - Smith, A. Ian

AU - Horlock, Duncan

AU - Murali, Aishwarya

AU - Kiriazis, Helen

AU - Du, Xiao-Jun

AU - Kaye, David M.

AU - Rajapakse, Niwanthi W.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - New Findings: What is the central question of this study? The aim was to determine the renoprotective effects of serelaxin in the setting of chronic heart failure. What are the main findings and its importance? Our data indicate that serelaxin can reduce renal fibrosis and inflammation in experimental heart failure. Currently, there are no effective treatments to rescue renal function in heart failure patients, and our data suggest that serelaxin might have the potential to reduce renal fibrosis and inflammation in heart failure. Abstract: Serelaxin has been demonstrated to attenuate renal fibrosis and inflammation in cardiorenal disease. In the present study, we tested the hypothesis that serelaxin can prevent the decline in renal function in dilated cardiomyopathy (DCM) by targeting renal fibrosis and inflammation. Male transgenic mice with DCM (n = 16) and their wild-type littermates (WT; n = 20) were administered either vehicle or serelaxin (500 μg kg−1 day−1; subcutaneous minipumps; 8 weeks). Cardiac function was assessed via echocardiography before and during the eighth week of serelaxin treatment. Renal function and inflammation as well as cardiac and renal fibrosis were assessed at the end of the study. Serelaxin had minimal effect on cardiac function (P ≥ 0.99). Tubulointerstitial and glomerular fibrosis were ∼3-fold greater in vehicle-treated DCM mice compared with vehicle-treated WT mice (P ≤ 0.001). Renal mRNA expression of Tnfα and Il1α were ∼4- and ∼3-fold greater, respectively, in vehicle-treated DCM mice compared with vehicle-treated WT mice (P ≤ 0.05). Tubulointerstitial and glomerular fibrosis were 46 and 45% less, respectively, in serelaxin-treated DCM mice than in vehicle-treated DCM mice (P ≤ 0.01). Renal cortical mRNA expression of Tnfα and Il1α were 56 and 58% less, respectively, in the former group compared with the latter (P ≤ 0.05). The urinary albumin:creatinine ratio was ∼3-fold greater in vehicle-treated DCM mice compared with vehicle-treated WT mice (P = 0.02). The urinary albumin:creatinine ratio was not significantly different between vehicle-treated DCM mice and serelaxin-treated DCM mice (P = 0.38). These data suggest that serelaxin can attenuate renal fibrosis and inflammation and has the potential to exert renoprotective effects in DCM.

AB - New Findings: What is the central question of this study? The aim was to determine the renoprotective effects of serelaxin in the setting of chronic heart failure. What are the main findings and its importance? Our data indicate that serelaxin can reduce renal fibrosis and inflammation in experimental heart failure. Currently, there are no effective treatments to rescue renal function in heart failure patients, and our data suggest that serelaxin might have the potential to reduce renal fibrosis and inflammation in heart failure. Abstract: Serelaxin has been demonstrated to attenuate renal fibrosis and inflammation in cardiorenal disease. In the present study, we tested the hypothesis that serelaxin can prevent the decline in renal function in dilated cardiomyopathy (DCM) by targeting renal fibrosis and inflammation. Male transgenic mice with DCM (n = 16) and their wild-type littermates (WT; n = 20) were administered either vehicle or serelaxin (500 μg kg−1 day−1; subcutaneous minipumps; 8 weeks). Cardiac function was assessed via echocardiography before and during the eighth week of serelaxin treatment. Renal function and inflammation as well as cardiac and renal fibrosis were assessed at the end of the study. Serelaxin had minimal effect on cardiac function (P ≥ 0.99). Tubulointerstitial and glomerular fibrosis were ∼3-fold greater in vehicle-treated DCM mice compared with vehicle-treated WT mice (P ≤ 0.001). Renal mRNA expression of Tnfα and Il1α were ∼4- and ∼3-fold greater, respectively, in vehicle-treated DCM mice compared with vehicle-treated WT mice (P ≤ 0.05). Tubulointerstitial and glomerular fibrosis were 46 and 45% less, respectively, in serelaxin-treated DCM mice than in vehicle-treated DCM mice (P ≤ 0.01). Renal cortical mRNA expression of Tnfα and Il1α were 56 and 58% less, respectively, in the former group compared with the latter (P ≤ 0.05). The urinary albumin:creatinine ratio was ∼3-fold greater in vehicle-treated DCM mice compared with vehicle-treated WT mice (P = 0.02). The urinary albumin:creatinine ratio was not significantly different between vehicle-treated DCM mice and serelaxin-treated DCM mice (P = 0.38). These data suggest that serelaxin can attenuate renal fibrosis and inflammation and has the potential to exert renoprotective effects in DCM.

KW - cardiorenal syndrome

KW - fibrosis

KW - inflammation

KW - serelaxin

UR - http://www.scopus.com/inward/record.url?scp=85056100969&partnerID=8YFLogxK

U2 - 10.1113/EP087189

DO - 10.1113/EP087189

M3 - Article

VL - 103

SP - 1593

EP - 1602

JO - Experimental Physiology

JF - Experimental Physiology

SN - 0958-0670

IS - 12

ER -